-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From January 5 to January 11, about 171 listed companies in Shanghai and Shenzhen were investigated by the agency
.
In the institutional survey list, a total of 45 companies have been surveyed by more than 20 institutions
.
On the whole, the mechanical equipment, electronics and medical biology sectors
.
Among them, there are 21 pharmaceutical and biological enterprises, and more than 460 institutions have received research
.
It is worth mentioning that among the 21 pharmaceutical companies, Huadong Medicine has attracted a lot of attention, and more than 340 institutions have participated in the survey; followed by Xianju Pharmaceutical and Teyi Pharmaceutical
.
Specifically, on January 6, Huadong Medicine released a record form of investor relations activities.
The announcement showed that on January 5, more than 280 institutional and individual investors including Goldman Sachs Group, Gao Yi Assets, BlackRock and Sequoia Capital A total of 525 people attended Huadong Medicine's online meeting
.
In the interactive exchanges with investors, the institution expressed concern about the company's industrial microbe product layout, CMO and CDMO business situation, the company's views on the future competition in the domestic industrial microbe field, and plans for industrial microbe R&D investment
.
Then on the 10th, Huadong Medicine issued another announcement saying: Huatai Pineapple, Toroa Management, Industrial Securities, Bank of Communications Schroders Fund, Ping An Asset, GF Fund, Nanhua Fund, Huisheng Fund, BlackRock Fund, Sequoia Capital , Guotai Junan Asset Management, Jiahe Fund, Minsheng Jiayin Fund, Qianhai United Fund, Guolian Fund, Taikang Assets and other 40 institutions investigated our company on January 7, 2022
.
The main contents of this investigation include key strategic layout directions, clinical results of some innovative drugs, and progress of liraglutide products
.
It is worth mentioning that a large number of enterprises also participated in the survey on the 10th
.
Including Hongze Research, Zhongtian Guofu Securities, Everbright Prudential Fund, Huaan Fund, Nufus Investment, Wangzheng Asset, Rushan Jianying Asset, Botong Investment, Freshwater Spring Investment, Fu Pei Investment, Xinghe Fund, Pengwan Fund , Bohong Asset, Chengsheng Investment and other 53 institutions
.
On January 5, 2022, Teyi Pharmaceutical issued an announcement saying: Huaan Securities Tan Guochao Li Changxing, Huaan Securities Research Institute Huang Jing, Xihong Private Equity Fund Yang Ying, Neoan Fund Zeng Guangkun, Capule Tang Han on January 5, 2022 Investigate our company every day
.
On the whole, the main content of the research of many institutions is on the cough medicine tablets
.
Subsequently, on January 10, Teyi Pharmaceutical issued an announcement stating that Zheshang Securities, Founder Self-operated, Southern Asset Management, Harvest Fund, Taiping Asset Fu Tao, SDIC UBS, Da Da Asset, Boyuan Fund, China Post 22 institutions including the Fund and Dacheng Fund also visited the company on January 10, 2022
.
The main contents of the survey include the progress of the company's NMN project, the impact of the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine" on the company, the company's revenue structure, and the proportion of sales revenue from various drugs
.
On January 6, 2022, Xianju Pharmaceutical also released a record of investor relations activities
.
The announcement shows that on January 5, 2022, the company was surveyed by 63 institutional units, and the types of institutions were insurance companies, others, fund companies, securities companies, and sunshine private equity institutions
.
In the survey, investors are more concerned about the medium and long-term strategic positioning of Xianju Pharmaceutical
.
In this regard, Xianju Pharmaceutical stated that the company will focus on the field of steroid hormones for a long time, complete and refine the hormone industry chain, continuously enrich the product structure of APIs and preparations, and focus on the improvement of comprehensive capabilities
.
.
In the institutional survey list, a total of 45 companies have been surveyed by more than 20 institutions
.
On the whole, the mechanical equipment, electronics and medical biology sectors
.
Among them, there are 21 pharmaceutical and biological enterprises, and more than 460 institutions have received research
.
It is worth mentioning that among the 21 pharmaceutical companies, Huadong Medicine has attracted a lot of attention, and more than 340 institutions have participated in the survey; followed by Xianju Pharmaceutical and Teyi Pharmaceutical
.
Specifically, on January 6, Huadong Medicine released a record form of investor relations activities.
The announcement showed that on January 5, more than 280 institutional and individual investors including Goldman Sachs Group, Gao Yi Assets, BlackRock and Sequoia Capital A total of 525 people attended Huadong Medicine's online meeting
.
In the interactive exchanges with investors, the institution expressed concern about the company's industrial microbe product layout, CMO and CDMO business situation, the company's views on the future competition in the domestic industrial microbe field, and plans for industrial microbe R&D investment
.
Then on the 10th, Huadong Medicine issued another announcement saying: Huatai Pineapple, Toroa Management, Industrial Securities, Bank of Communications Schroders Fund, Ping An Asset, GF Fund, Nanhua Fund, Huisheng Fund, BlackRock Fund, Sequoia Capital , Guotai Junan Asset Management, Jiahe Fund, Minsheng Jiayin Fund, Qianhai United Fund, Guolian Fund, Taikang Assets and other 40 institutions investigated our company on January 7, 2022
.
The main contents of this investigation include key strategic layout directions, clinical results of some innovative drugs, and progress of liraglutide products
.
It is worth mentioning that a large number of enterprises also participated in the survey on the 10th
.
Including Hongze Research, Zhongtian Guofu Securities, Everbright Prudential Fund, Huaan Fund, Nufus Investment, Wangzheng Asset, Rushan Jianying Asset, Botong Investment, Freshwater Spring Investment, Fu Pei Investment, Xinghe Fund, Pengwan Fund , Bohong Asset, Chengsheng Investment and other 53 institutions
.
On January 5, 2022, Teyi Pharmaceutical issued an announcement saying: Huaan Securities Tan Guochao Li Changxing, Huaan Securities Research Institute Huang Jing, Xihong Private Equity Fund Yang Ying, Neoan Fund Zeng Guangkun, Capule Tang Han on January 5, 2022 Investigate our company every day
.
On the whole, the main content of the research of many institutions is on the cough medicine tablets
.
Subsequently, on January 10, Teyi Pharmaceutical issued an announcement stating that Zheshang Securities, Founder Self-operated, Southern Asset Management, Harvest Fund, Taiping Asset Fu Tao, SDIC UBS, Da Da Asset, Boyuan Fund, China Post 22 institutions including the Fund and Dacheng Fund also visited the company on January 10, 2022
.
The main contents of the survey include the progress of the company's NMN project, the impact of the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine" on the company, the company's revenue structure, and the proportion of sales revenue from various drugs
.
On January 6, 2022, Xianju Pharmaceutical also released a record of investor relations activities
.
The announcement shows that on January 5, 2022, the company was surveyed by 63 institutional units, and the types of institutions were insurance companies, others, fund companies, securities companies, and sunshine private equity institutions
.
In the survey, investors are more concerned about the medium and long-term strategic positioning of Xianju Pharmaceutical
.
In this regard, Xianju Pharmaceutical stated that the company will focus on the field of steroid hormones for a long time, complete and refine the hormone industry chain, continuously enrich the product structure of APIs and preparations, and focus on the improvement of comprehensive capabilities
.
